Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phase 2 blood-pressure endpoints, FDA meeting timelines, stock-based compensation for a science-driven team鈥擬ineralys Therapeutics鈥� SEC disclosures are packed with biotech jargon that can overwhelm even seasoned analysts. If you have ever scrolled through a 300-page report looking for a single dosing update, you know the challenge. That complexity makes Mineralys Therapeutics insider trading Form 4 transactions and clinical milestones difficult to spot when seconds matter.
Stock Titan solves the problem. Our AI reads every Mineralys Therapeutics quarterly earnings report 10-Q filing the moment it hits EDGAR, extracts cash-runway tables, and flags enrollment progress so you don鈥檛 have to. It highlights Mineralys Therapeutics Form 4 insider transactions real-time, translates risk-factor language into plain English, and stitches together cross-references so you get Mineralys Therapeutics SEC filings explained simply. Whether you need a quick Mineralys Therapeutics earnings report filing analysis or are understanding Mineralys Therapeutics SEC documents with AI before a meeting, our platform delivers.
Use the dashboard to monitor upcoming trials stated in the Mineralys Therapeutics annual report 10-K simplified, drill into pipeline funding clues hidden in the Mineralys Therapeutics proxy statement executive compensation, or receive instant alerts when an executive executes Mineralys Therapeutics executive stock transactions Form 4. Material study readouts? They surface through Mineralys Therapeutics 8-K material events explained. AG真人官方-time updates, concise AI-powered summaries, and form-specific filters turn dense documents into actionable insights鈥攆reeing you to focus on whether lorundrostat鈥檚 next data cut could move the share price.
Mineralys Therapeutics (MLYS) 鈥� Form 4 filed 30-Jul-2025
CFO & Secretary Adam S. Levy reported open-market sales of 73,678 common shares across three trading days:
- 28-Jul-2025: 12,946 sh. at a weighted avg. $14.0432
- 29-Jul-2025: 807 sh. at $14.0048
- 30-Jul-2025: 51,500 sh. at $14.7023 and 8,425 sh. at $15.0983
Levy now directly owns 132,934 shares. Arithmetic implies his stake fell from 206,612 to 132,934 shares, a reduction of roughly 36 %. No derivative transactions were reported, and the filing does not state that the sales were executed under a Rule 10b5-1 trading plan.